Independent anti-corruption organisation Transparency International (TI) said on Tuesday that there are large discrepancies in the prices paid for vaccines, revealing that South Africa paid an average of 25% more per dose for the Oxford/AstraZeneca vaccine, compared with the European Union. South Africa halted the use of the Oxford/AstraZeneca vaccine, developed by the Serum Institute of India (SII), in February after its efficacy to treat the SARS-CoV-2 variant of the Covid-19 virus was called into question.
from Engineering News | Home https://ift.tt/3yAXHZQ
